Patient, disease, and transplant characteristics
| Variable . | Myeloablative . | Reduced intensity . | P . |
|---|---|---|---|
| No. of patients | 526 | 799 | |
| Age, n (%), y | <.001 | ||
| 18-54 | 381 (72) | 308 (39) | |
| 55-70 | 145 (28) | 491 (61) | |
| Sex, n (%) | .03 | ||
| Male | 279 (53) | 472 (59) | |
| Female | 247 (47) | 327 (41) | |
| Performance score, n (%) | .02 | ||
| 90-100 | 267 (51) | 460 (58) | |
| ≤80 | 243 (46) | 307 (38) | |
| Not reported | 16 (3) | 32 (4) | |
| Comorbidity score, n (%) | .15 | ||
| 0-2 | 288 (55) | 392 (49) | |
| ≥3 | 238 (45) | 407 (51) | |
| CMV serostatus, n (%) | .70 | ||
| Negative | 157 (30) | 250 (31) | |
| Positive | 364 (69) | 544 (68) | |
| Not reported | 5 (<1) | 5 (<1) | |
| Disease, n (%) | <.001 | ||
| AML | 329 (63) | 489 (61) | |
| ALL | 136 (26) | 150 (19) | |
| MDS | 61 (12) | 160 (20) | |
| Disease status: AML/ALL, n (%) | <.001 | ||
| First complete remission | 235 (45) | 387 (48) | |
| Second complete remission | 114 (22) | 146 (18) | |
| Relapse | 116 (22) | 106 (13) | |
| Disease status: MDS, n (%) | <.001 | ||
| RA/RARS/RCMD | 9 (2) | 21 (3) | |
| RAEB-1/RAEB-2 | 50 (10) | 135 (17) | |
| Not reported | 2 (<1) | 4 (<1) | |
| Cytogenetic risk: AML, n (%) | .80 | ||
| Favorable | 28 (9) | 33 (7) | |
| Intermediate | 261 (79) | 398 (81) | |
| Poor | 28 (9) | 39 (8) | |
| Not reported | 12 (3) | 19 (4) | |
| Cytogenetic risk: ALL, n (%) | .98 | ||
| Normal | 25 (18) | 28 (19) | |
| Poor | 65 (48) | 73 (49) | |
| Not reported | 46 (34) | 49 (33) | |
| Cytogenetic risk: MDS, n (%) | .95 | ||
| Intermediate | 36 (59) | 91 (57) | |
| Poor | 16 (26) | 45 (28) | |
| Not reported | 9 (15) | 24 (15) | |
| Disease risk index, n (%) | .01 | ||
| Low | 25 (5) | 26 (3) | |
| Intermediate | 261 (50) | 463 (58) | |
| High/very high | 217 (41) | 268 (34) | |
| Not reported | 23 (4) | 42 (5) | |
| Myeloablative regimens, n (%) | NA | ||
| TBI/fludarabine | 171 (33) | … | |
| TBI/other agents | 51 (10) | … | |
| Busulfan/cyclophosphamide | 76 (14) | … | |
| Busulfan/fludarabine | 68 (13) | … | |
| Busulfan/cyclophosphamide/fludarabine | 114 (22) | … | |
| Melphalan/fludarabine ± thiotepa | 46 (9) | … | |
| Reduced-intensity regimens, n (%) | |||
| TBI/busulfan/fludarabine | … | 17 (2) | |
| TBI/cyclophosphamide/fludarabine | … | 668 (84) | |
| TBI/melphalan/fludarabine | … | 42 (5) | |
| Busulfan/fludarabine | … | 9 (1) | |
| Melphalan/fludarabine | … | 63 (17) | |
| Graft type, n (%) | <.001 | ||
| Bone marrow | 181 (34) | 464 (58) | |
| Peripheral blood | 345 (66) | 335 (42) | |
| GVHD prophylaxis | |||
| Posttransplant cyclophosphamide/calcineurin inhibitor/mycophenolate | 526 (100) | 799 (100) | NA |
| Transplant period, n (%) | .28 | ||
| 2008-2012 | 94 (18) | 162 (20) | |
| 2013-2016 | 432 (82) | 637 (80) |
| Variable . | Myeloablative . | Reduced intensity . | P . |
|---|---|---|---|
| No. of patients | 526 | 799 | |
| Age, n (%), y | <.001 | ||
| 18-54 | 381 (72) | 308 (39) | |
| 55-70 | 145 (28) | 491 (61) | |
| Sex, n (%) | .03 | ||
| Male | 279 (53) | 472 (59) | |
| Female | 247 (47) | 327 (41) | |
| Performance score, n (%) | .02 | ||
| 90-100 | 267 (51) | 460 (58) | |
| ≤80 | 243 (46) | 307 (38) | |
| Not reported | 16 (3) | 32 (4) | |
| Comorbidity score, n (%) | .15 | ||
| 0-2 | 288 (55) | 392 (49) | |
| ≥3 | 238 (45) | 407 (51) | |
| CMV serostatus, n (%) | .70 | ||
| Negative | 157 (30) | 250 (31) | |
| Positive | 364 (69) | 544 (68) | |
| Not reported | 5 (<1) | 5 (<1) | |
| Disease, n (%) | <.001 | ||
| AML | 329 (63) | 489 (61) | |
| ALL | 136 (26) | 150 (19) | |
| MDS | 61 (12) | 160 (20) | |
| Disease status: AML/ALL, n (%) | <.001 | ||
| First complete remission | 235 (45) | 387 (48) | |
| Second complete remission | 114 (22) | 146 (18) | |
| Relapse | 116 (22) | 106 (13) | |
| Disease status: MDS, n (%) | <.001 | ||
| RA/RARS/RCMD | 9 (2) | 21 (3) | |
| RAEB-1/RAEB-2 | 50 (10) | 135 (17) | |
| Not reported | 2 (<1) | 4 (<1) | |
| Cytogenetic risk: AML, n (%) | .80 | ||
| Favorable | 28 (9) | 33 (7) | |
| Intermediate | 261 (79) | 398 (81) | |
| Poor | 28 (9) | 39 (8) | |
| Not reported | 12 (3) | 19 (4) | |
| Cytogenetic risk: ALL, n (%) | .98 | ||
| Normal | 25 (18) | 28 (19) | |
| Poor | 65 (48) | 73 (49) | |
| Not reported | 46 (34) | 49 (33) | |
| Cytogenetic risk: MDS, n (%) | .95 | ||
| Intermediate | 36 (59) | 91 (57) | |
| Poor | 16 (26) | 45 (28) | |
| Not reported | 9 (15) | 24 (15) | |
| Disease risk index, n (%) | .01 | ||
| Low | 25 (5) | 26 (3) | |
| Intermediate | 261 (50) | 463 (58) | |
| High/very high | 217 (41) | 268 (34) | |
| Not reported | 23 (4) | 42 (5) | |
| Myeloablative regimens, n (%) | NA | ||
| TBI/fludarabine | 171 (33) | … | |
| TBI/other agents | 51 (10) | … | |
| Busulfan/cyclophosphamide | 76 (14) | … | |
| Busulfan/fludarabine | 68 (13) | … | |
| Busulfan/cyclophosphamide/fludarabine | 114 (22) | … | |
| Melphalan/fludarabine ± thiotepa | 46 (9) | … | |
| Reduced-intensity regimens, n (%) | |||
| TBI/busulfan/fludarabine | … | 17 (2) | |
| TBI/cyclophosphamide/fludarabine | … | 668 (84) | |
| TBI/melphalan/fludarabine | … | 42 (5) | |
| Busulfan/fludarabine | … | 9 (1) | |
| Melphalan/fludarabine | … | 63 (17) | |
| Graft type, n (%) | <.001 | ||
| Bone marrow | 181 (34) | 464 (58) | |
| Peripheral blood | 345 (66) | 335 (42) | |
| GVHD prophylaxis | |||
| Posttransplant cyclophosphamide/calcineurin inhibitor/mycophenolate | 526 (100) | 799 (100) | NA |
| Transplant period, n (%) | .28 | ||
| 2008-2012 | 94 (18) | 162 (20) | |
| 2013-2016 | 432 (82) | 637 (80) |
NA, not applicable; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ringed sideroblast; RCMD, refractory anemia with multilineage dysplasia.